Dr. Michael Kalos is an internationally recognized expert in T cell therapy and immunotherapy and brings over 25 years of experience and expertise in cell therapy, oncology vaccines, and immune-oncology. Prior to his career in the biopharmaceutical sector, Dr. Kalos spent 10 years in academia. where he focused on the development of integrated translational biomarker programs to support the development of cell therapy and immunotherapy programs. The laboratory he founded and directed at the University of Pennsylvania played a key role in the success of the clinical cell therapy program at Penn, including the development of the CTLo19 program, which was licensed to Novartis and led to Kymriah, the first approved CART cell therapy product. Dr. Kalos obtained his Ph.D. from the University of Minnesota and completed post-doctoral training in the laboratory of Phil Greenberg at the Fred Hutchinson Cancer Research Center.
Org chart
This person is not in the org chart
Teams
Offices
This person is not in any offices
IMV
IMV - multiple clinical-stage candidates in immuno-oncology and infectious disease, with a focus on combination therapies.
